13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001819257
Total reported value
$645.5M
$645.5M
28 檔
45.0%
The Q4 2025 SEC filing reveals that Patient Square Capital LP held a total portfolio value of $645.5M, covering 28 public equity positions.
In Q4 2025, Patient Square Capital LP displayed an active expansion posture, initiating 9 new positions and adding to 11 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 37.93% | +3.84% | -34.57% | |
| 2 | INSM | Insmed Inc | Stock-Healthcare | 9.95% | -4.57% | EXIT | |
| 3 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 5.05% | +0.95% | +186.47% | |
| 4 | ARGX | Argenx Se - Adr | Stock-Healthcare | 4.68% | -1.45% | +67.74% | |
| 5 | ONC | Beone Medicines Ltd-adr | Stock-Other | 4.51% | -0.27% | — | |
| 6 | ABVX | Abivax Sa-adr | Stock-Other | 3.75% | +1.86% | -14.38% | |
| 7 | PHVS | Pharvaris N.V. | Stock-Other | 3.22% | +1.13% | +57.13% | |
| 8 | EYPT | Eyepoint Inc | Stock-Other | 3.05% | -0.22% | -22.91% | |
| 9 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 2.77% | — | — | |
| 10 | CELC | Celcuity Inc | Stock-Other | 2.56% | -1.92% | EXIT | |
| 11 | COGT | Cogent Biosciences Inc | Stock-Other | 2.41% | -1.52% | — | |
| 12 | KYMR | Kymera Therapeutics Inc | Stock-Other | 2.32% | -0.64% | +50.12% | |
| 13 | LQDA | Liquidia CORP | Stock-Other | 1.68% | — | -43.25% | |
| 14 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 1.47% | -0.26% | — | |
| 15 | ALLO | Allogene Therapeutics Inc | Stock-Other | 1.46% | +0.14% | +66.49% | |
| 16 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 1.32% | +0.23% | +20.00% | |
| 17 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.31% | -0.28% | — | |
| 18 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 1.31% | -0.17% | — | |
| 19 | OCUL | Ocular Therapeutix Inc | Stock-Other | 1.27% | — | -31.47% | |
| 20 | IRON | Disc Medicine Inc | Stock-Other | 1.26% | — | — | |
| 21 | AVTX | Avalo Therapeutics Inc | Stock-Other | 1.21% | — | +211.97% | |
| 22 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.05% | -0.01% | EXIT | |
| 23 | ELVN | Enliven Therapeutics Inc | Stock-Other | 1.02% | +0.28% | +22.84% | |
| 24 | ASMB | Assembly Biosciences Inc | Stock-Other | 0.92% | -0.67% | EXIT | |
| 25 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 0.91% | — | +10.65% | |
| 26 | RCUS | Arcus Biosciences Inc | Stock-Other | 0.87% | +0.95% | — | |
| 27 | CATX | Perspective Therapeutics Inc | Stock-Other | 0.67% | -1.20% | EXIT | |
| 28 | HROW | Harrow Inc | Stock-Other | 0.07% | -1.03% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | MIRM | Mirum Pharmaceuticals Inc | +3% | +186.47% | Add |
| 2 | ARGX | Argenx Se - Adr | +1.6% | +67.74% | Add |
| 3 | CELC | Celcuity Inc | +1.2% | +20.00% | Add |
| 4 | KYMR | Kymera Therapeutics Inc | +0.9% | +50.12% | Add |
| 5 | PHVS | Pharvaris N.V. | +0.9% | +57.13% | Add |
| 6 | AVTX | Avalo Therapeutics Inc | +0.9% | +211.97% | Add |
| 7 | ALLO | Allogene Therapeutics Inc | +0.5% | +66.49% | Add |
| 8 | CATX | Perspective Therapeutics Inc | +0.4% | +224.29% | Add |
| 9 | ABVX | Abivax Sa-adr | +0.3% | -14.38% | Trim |
| 10 | DNTH | Dianthus Therapeutics Inc | — | +20.00% | Add |
| 11 | ASMB | Assembly Biosciences Inc | 0% | -6.05% | Trim |
| 12 | IRON | Disc Medicine Inc | -0.1% | — | Unchanged |
| 13 | AMLX | Amylyx Pharmaceuticals Inc | -0.2% | +10.65% | Add |
| 14 | ELVN | Enliven Therapeutics Inc | -0.4% | +22.84% | Add |
| 15 | LQDA | Liquidia CORP | -0.8% | -43.25% | Trim |
| 16 | EYPT | Eyepoint Inc | -0.8% | -22.91% | Trim |
| 17 | OCUL | Ocular Therapeutix Inc | -1% | -31.47% | Trim |
| 18 | INSM | Insmed Inc | -2.6% | -18.20% | Trim |
| 19 | ROIV | Roivant Sciences Ltd. | -12.6% | -34.57% | Trim |
| 20 | ONC | Beone Medicines Ltd-adr | — | NEW | New buy |
| 21 | 430 | Terns Pharmaceuticals Inc | — | NEW | New buy |
| 22 | CDTX | Cidara Therapeutics Inc | — | EXIT | Sold out |
| 23 | COGT | Cogent Biosciences Inc | — | NEW | New buy |
| 24 | DBVT | Dbv Technologies Sa-spon Adr | — | NEW | New buy |
| 25 | XENE | Xenon Pharmaceuticals Inc | — | NEW | New buy |
| 26 | ARQT | Arcutis Biotherapeutics Inc | — | NEW | New buy |
| 27 | AGIO | Agios Pharmaceuticals Inc | — | EXIT | Sold out |
| 28 | SYRE | Spyre Therapeutics Inc | — | NEW | New buy |
| 29 | QURE | uniQure N.V. | — | EXIT | Sold out |
| 30 | RCUS | Arcus Biosciences Inc | — | NEW | New buy |
| 31 | NRIX | Nurix Therapeutics Inc | — | EXIT | Sold out |
| 32 | GERN | Geron CORP | — | EXIT | Sold out |
| 33 | HROW | Harrow Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Patient Square Capital LP reported a total U.S. public equity portfolio value of $645.5M across 28 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ROIV, INSM, MIRM) accounted for 45.0% of total reported equity market value during Q4 2025.
Top New Position Initiated
ONC
市值: $21.1M
Top Position Liquidated / Trimmed
CDTX
前期市值: $11.6M
During Q4 2025, Patient Square Capital LP's top holdings by market value included ROIV (37.9%)、INSM (9.9%)、MIRM (5.0%). The largest single position, ROIV, represented 37.9% of total portfolio value.
In Q4 2025, Patient Square Capital LP made 32 total portfolio adjustments, initiating 9 new buys, adding to 11 positions, trimming 7 holdings, and fully liquidating 5 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.